These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 19060594)

  • 21. Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women?
    Lewis S
    Am Heart J; 2007 Feb; 153(2):182-8. PubMed ID: 17239675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy.
    Cella D; Fallowfield LJ
    Breast Cancer Res Treat; 2008 Jan; 107(2):167-80. PubMed ID: 17876703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review.
    Poole R; Paridaens R
    Curr Opin Oncol; 2007 Nov; 19(6):564-72. PubMed ID: 17906453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Translating trial data into patients benefits: making the right choice.
    Chlebowski RT
    Breast; 2008 Apr; 17 Suppl 3():S9-15. PubMed ID: 18367397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The evolution of adjuvant endocrine therapy: developments since St Gallen 2005.
    Smith IE; Arnedos M
    Breast; 2007 Dec; 16 Suppl 2():S4-9. PubMed ID: 17764939
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sequential therapy with tamoxifen and aromatase inhibitors in early-stage postmenopausal breast cancer: a review of the evidence.
    Litsas G
    Oncol Nurs Forum; 2008 Jul; 35(4):714-21. PubMed ID: 18591176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Current adjuvant endocrine treatment of breast cancer].
    Dedes KJ; Gabriel N; Fink D
    Gynakol Geburtshilfliche Rundsch; 2008; 48(3):130-7. PubMed ID: 18566529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer.
    Dixon JM
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):453-63. PubMed ID: 18366292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of bone disease in patients undergoing hormonal therapy for breast cancer.
    Mirza FS
    Endocrinol Metab Clin North Am; 2011 Sep; 40(3):549-62, viii. PubMed ID: 21889720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer.
    Perez EA
    Ann Oncol; 2007 Sep; 18 Suppl 8():viii26-35. PubMed ID: 17890211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials?
    Tang SC
    Cancer Invest; 2008 Jun; 26(5):481-90. PubMed ID: 18568770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aromatase inhibitors in the management of early breast cancer.
    Nabholtz JM
    Eur J Surg Oncol; 2008 Nov; 34(11):1199-207. PubMed ID: 18359182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Aromatase inhibitors in the adjuvant treatment of postmenopausal patients with early breast cancer: a little, a lot or no way?].
    Perey L; Zaman K
    Rev Med Suisse; 2007 Oct; 3(130):2406, 2408-10, 2412. PubMed ID: 18062504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identifying menopause in breast cancer patients: considerations and implications.
    Clemons M; Simmons C
    Breast Cancer Res Treat; 2007 Aug; 104(2):115-20. PubMed ID: 17061039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer.
    Rutqvist LE; Johansson H;
    Acta Oncol; 2007; 46(2):133-45. PubMed ID: 17453361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current controversies in extended adjuvant endocrine therapy for early breast cancer.
    Snoj N; Paridaens R; Cufer T
    Curr Opin Oncol; 2008 Nov; 20(6):627-33. PubMed ID: 18841043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aromatase inhibitors and cardiac toxicity: getting to the heart of the matter.
    Gandhi S; Verma S
    Breast Cancer Res Treat; 2007 Nov; 106(1):1-9. PubMed ID: 17211535
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Addressing the future: combination with targeted therapies, adjuvant setting and beyond.
    Goss PE
    Anticancer Drugs; 2008 Mar; 19 Suppl 2():S3-5. PubMed ID: 18337641
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Postmenopausal women with hormone receptor-positive breast cancer: balancing benefit and toxicity from aromatase inhibitors.
    Ingle JN
    Breast; 2013 Aug; 22 Suppl 2():S180-3. PubMed ID: 24074784
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectively nursing patients receiving aromatase inhibitor therapy.
    Wengström Y
    Breast; 2008 Jun; 17(3):227-38. PubMed ID: 18077168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.